BioMedNewsBreaks

WednesdayOct 26, 2022 1:35 pm

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Expedite Return to Work, Play Following Concussive Episode

Odyssey Health (OTC: ODYY), a medical company with a focus in the area of life-saving medical solutions, has developed a fully synthetic, non-naturally occurring neurosteroid known as PRV-002 intended to treat concussion or mild traumatic brain injury (“mTBI”). “Designed to be administered within a few minutes of a concussive episode, PRV-002 induces an intracellular steroid receptor in brain cells, with the stimulation of this receptor activating multiple gene response elements that promote transcription of anti-inflammatories, antioxidants and efflux channels that remove excess fluid and debris. To put it simply, PRV-002 is intended to reduce swelling, oxidative stress and inflammation, and…

Continue Reading

WednesdayOct 26, 2022 12:43 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Approval of Second Clinical Trial Site for Phase 1 Study

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has added Rutgers Cancer Institute of New Jersey (“RCINJ”) as a clinical trial site for its phase 1 CycloSam study. RCINJ has been approved to begin enrolling patients into the study, which will evaluate the effectiveness of CycloSam in treating patients with bone cancer. According to the announcement, RCINJ is part of Rutgers Health and is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, a designation granted to institutions based on scientific leadership, resources and track record of…

Continue Reading

WednesdayOct 26, 2022 12:31 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its VP of R&D, James Kuo, M.D. M.B.A, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. According to the update, Silo Pharma is a sponsor of the three-day event slated to take place Nov. 3-5, 2022, in Miami, Florida. Dr. Kuo will speak on the Mainstream Pharma and Psychedelics panel scheduled for Saturday, Nov. 5, on the Science Main Stage. “It will be an honor to join other industry leaders as…

Continue Reading

WednesdayOct 26, 2022 11:19 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it is supporting initiatives to raise awareness of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Epidermolysis Bullosa Global Awareness Week is Oct. 25-31, 2022. “In severe cases of epidermolysis bullosa, or EB, the very fragile skin tears easily and forms painful blisters and open wounds that do not heal quickly,” said Alexandra Mancini, SVP of Clinical and Regulatory Affairs for InMed. “EB is a very important but rare disease that does not get the attention it deserves. EB Awareness…

Continue Reading

TuesdayOct 25, 2022 12:06 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q3 2022 Results Conference Call

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced that it will hold a conference call at 4:30 p.m ET on Thursday, Nov. 10, 2022. HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the call, during which time they will discuss the company’s results for the third quarter ended Sept. 30, 2022, and review recent announcements, ongoing initiatives, and key 2022 and anticipated 2023 milestones, followed by a question-and-answer period. A presentation will accompany the…

Continue Reading

MondayOct 24, 2022 2:31 pm

BioMedNewsBreaks – Octane’s Upcoming Forum to Showcase Visionary Speakers, Latest Advances in Medical Technology Sector

Octane, an organization leading the Southern California technology and medical technology business ecosystem, today announced that the 2022 Medical Innovation Forum will be held on Oct. 27-28 at the Irvine Marriott in Irvine, California. The two-day event will feature the most visionary speakers from the medical technology sector, showcase the latest advances, and offer access to unparalleled educational opportunities and the potential to network, explore synergies and foster long-term partnerships with fellow professionals. Investors looking for untapped opportunities will benefit from one-on-one, private meetings organized with fully vetted, early stage companies that are at the cutting edge of innovation in the medical…

Continue Reading

MondayOct 24, 2022 1:49 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at LD Micro Main Event XV

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, has announced that its Director of Investor Relations, Joshua Phillipson, will attend and present at the LD Micro Main Event XV. The leading small cap investor conference is taking place in Los Angeles on Oct. 25 to 27, 2022, and will showcase more than 200 companies. Phillipson is scheduled to present at 9 a.m. PT on Tuesday, Oct. 25, in Track 3, and will discuss BiondVax’s investment case, including its highly experienced leadership team, innovative…

Continue Reading

MondayOct 24, 2022 1:02 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions

Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article. “Originally founded in 2010, Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Increasingly and over the past two decades, clinical research on psychedelics, most notably psilocybin and methylenedioxymethamphetamine…

Continue Reading

FridayOct 21, 2022 3:05 pm

BioMedNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Patented Breakthrough Technology Poised to Disrupt ECG Patch Market

HeartBeam (NASDAQ: BEAT) recently received a patent from the United States Patent and Trademark Office for its 12-lead electrocardiogram (“ECG”) patch monitor for the detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia. “The new patent expands on a previously granted patent for a 12-lead ECG patch monitor technology. HeartBeam noted that the patent opens a pathway to a disruptive ischemia and arrhythmia detection ECG patch product. In addition, the innovation builds on HeartBeam’s growing intellectual property portfolio that could enable 12-lead ECG diagnostics outside of a medical setting… Currently, the ECG patch monitor market is limited to detecting arrhythmias…

Continue Reading

FridayOct 21, 2022 2:09 pm

BioMedNewsBreaks – IBN, InvestorWire to Expand Virtual Presence of Octane’s Medical Innovation Forum

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced that it will serve as an official media partner for Octane’s upcoming Medical Innovation Forum. In addition, IBN’s InvestorWire (“IW”) brand was engaged as the official newswire for the event. Slated to be held in a hybrid format on Oct. 27-28, 2022, attendees will be able to participate virtually as well as on-site at the Irvine Marriott in Irvine, California. Octane’s mission is to enable a broader business ecosystem in Southern California, facilitating tech and medtech ventures to flourish with a target of generating more than 55,000 high-paying technology jobs in the…

Continue Reading